Acute Myeloid Leukemia (AML)

Alrizomadlin (APG-115)

Alrizomadlin is an orally administered, selective, small-molecule inhibitor of the MDM2 protein. Alrizomadlin has strong binding affinity to MDM2 and is designed to activate tumor suppression activity of p53 by blocking the MDM2-p53 protein-protein interaction.

Anna Halpern, MD

Institution
Fred Hutchinson Cancer Research Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
I am both a hematologist-oncologist and a clinical researcher. Along with caring for you, I conduct research focused on hematologic (blood-based) malignancies — specifically, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), polycythemia vera, essential thrombocythemia and myelofibrosis. My overarching research aim is to help adults with these diseases have better outcomes by developing and testing evidence-based therapies that are tailored to your unique needs as a patient. I design and conduct clinical trials testing novel care concepts for people with AML and MDS, and I use

Kanwaldeep Mallhi, MD

Institution
Roswell Park Comprehensive Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric
About
Dr. Kanwaldeep Mallhi is a pediatric oncologist and hematologist who specializes in nonmalignant blood disorders in children. These disorders include immunodeficiencies, bone marrow failure and metabolic errors. She is an expert in pediatric blood stem cell transplants, and her research focuses on alternative donor sources and the development of reduced-intensity conditioning regimens, which use radiation, chemotherapy or other procedures to remove diseased or failing cells prior to transplant.

Researchers Uncover How MN1 Overexpression Causes AML

Original Publication Date
Article Source
External Web Content
Meningioma-1 (MN1) is a protein whose overexpression has been linked to acute myeloid leukemia (AML) and brain tumors, and 70% to 80% of AML patients with high overexpression of MN1 die within two years. Yet the mechanism by which MN1 causes these diseases has largely remained a…

RARA Agonist Plus Azacitidine Shows Encouraging Activity in Relapsed/Refractory AML

Original Publication Date
Article Source
External Web Content
The novel agentSY-1425 combined with azacitidine appears to be active in retinoic acid receptor alpha (RARA) superenhancer–positive newly diagnosed and relapsed or refractory acute myeloid leukemia (AML), according to the results of a phase II trial presented at the 2020 American…

Nathan Punwani, MD, MPH

Institution
Cedars-Sinai
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
About
Dr. Punwani is a hematologist/oncologist with the Blood and Marrow Transplant Program at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai. He earned his BA from Lehigh University, an MPH in Health Care Management & Policy from Harvard School of Public Health and his MD from Drexel University College of Medicine. He did his Internal Medicine Residency at George Washington Unviersity Hospital and his Fellowships in Hematology and Oncology at the University of Southern California. Dr. Punwani is board certified in Internal Medicine and is both researcher and clinician with more

Ivana Gojo, MD

Institution
Johns Hopkins Sidney Kimmel Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Chronic Lymphocytic Leukemia (CLL)
About
Dr. Ivana Gojo is a Hematologist/Oncologist in Baltimore. Her clinical focus is on diagnosis and management of patients with acute leukemias (AML, ALL) and other myeloid malignancies (MDS, MPNs, CML), with emphasis on the development of novel therapeutic approaches for these diseases. She is nationally and internationally recognized expert in clinical translation of novel therapeutics for acute leukemias and principal investigator on multiple multi-center investigator-initiated studies. Dr. Gojo joined the Johns Hopkins faculty in 2012 as the Co-Director of Leukemia Drug Development Program

Catherine Chittick, RN, BSN

Institution
Massachusetts General Hospital Cancer Center
Physician Status
available for consultation
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
About
Catherine Chittick, RN, BSN is an oncology nurse at the Massachusetts General Hospital (MGH), where she has been employed for five years since the start of her career. After graduating from Sacred Heart University (Fairfield, CT) School of Nursing in 2015, Catherine joined the nursing profession as a registered nurse at the MGH as part of the eCare Nursing Residency program for new graduates. She has both outpatient and inpatient experience, working first in an outpatient infusion nurse caring for leukemia and bone marrow transplant patients before moving inpatient to care for patients with

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.